The global dry powder inhaler market is projected to reach USD 31.6 billion by 2036, increasing from USD 21.6 billion in 2025, according to Future Market Insights (FMI). The market is estimated at USD 22.4 billion in 2026 and is forecast to expand at a compound annual growth rate (CAGR) of 3.5% between 2026 and 2036.

Growing asthma and chronic obstructive pulmonary disease (COPD) prevalence, increasing demand for maintenance inhalation therapies, wider access to respiratory medications and advances in inhaler technology are supporting market expansion. The rising adoption of combination therapies and once-daily inhalation treatments is also creating opportunities for pharmaceutical manufacturers. India, ASEAN and China are among the markets presenting attractive growth opportunities.

Request For a Report Sample: https://www.futuremarketinsights.com/reports/sample/rep-gb-5150

The Short Version

· Market expansion: The dry powder inhaler market is forecast to increase from USD 22.4 billion in 2026 to USD 31.6 billion by 2036, registering a 3.5% CAGR.

· Product leadership: Multi-dose dry powder inhalers account for 59.4% of product demand in 2026.

· Indication leadership: Asthma represents 42.7% of the indication category, followed by COPD at 38.9%.

· Geographical opportunities: India records the highest country-wise CAGR at 5.2%, followed by ASEAN at 4.7% and China at 4.4%.

Three Numbers That Matter

USD 31.6 billion: The projected global market value by 2036, reflecting continued demand for inhaled treatments across chronic respiratory conditions.

59.4%: The estimated share of multi-dose dry powder inhalers in 2026. Their convenience and pre-metered dosing capabilities support their leading position in maintenance respiratory treatment.

42.7%: The projected share of asthma within the indication category in 2026. The substantial population requiring daily controller therapies supports demand for dry powder inhalation products.

Where Growth Is Strongest

FMI's country-wise comparison identifies several attractive markets for dry powder inhaler manufacturers and healthcare investors.

· India – 5.2% CAGR: A large asthma and COPD patient population, strong local manufacturing capabilities and availability of low-cost capsule inhalers support market expansion.

· ASEAN – 4.7% CAGR: Increasing respiratory disease diagnosis, air pollution and improving public healthcare access are supporting inhaler adoption.

· China – 4.4% CAGR: Expanding triple-therapy applications and the approval of additional indications for once-daily inhalers are creating opportunities.

· United States – 3.3% CAGR: Established respiratory healthcare infrastructure and continued demand for maintenance treatments support steady market development, although generic competition creates pricing pressure.

· Canada – 3.1% CAGR: Established public drug plans and recurring maintenance therapy demand support gradual market growth.

· Spain – 2.9% CAGR: An aging population and COPD treatment requirements support inhaler consumption.

· France – 2.4% CAGR: Generic competition and growing interest in lower-carbon inhalation devices influence market expansion.

India represents the fastest-growing country in FMI's comparison, while France records the slowest growth among the profiled markets.

Who Is Moving: Competitive Developments and Key Players

The competitive environment is shaped by respiratory drug innovation, combination therapy development, generic product launches and improvements in inhaler device technology. Manufacturers are strengthening their portfolios through once-daily triple therapies, cost-effective generic combinations and advanced inhalation delivery systems.

Several developments highlighted in the report illustrate this activity:

· October 2025: GSK announced positive pivotal Phase III data for a next-generation low-carbon version of Ventolin using HFA-152a, with the potential to reduce emissions by 92% per inhaler.

· January 2026: China approved Trelegy Ellipta for adults with uncontrolled asthma, expanding its treatment applications beyond COPD.

· May 2026: GSK presented 33 abstracts at the American Thoracic Society (ATS) 2026 meeting, including research involving single-inhaler triple therapy.

· July 2026: AstraZeneca reported a 17% increase in Breztri revenue at constant exchange rates during the first half of 2026, highlighting demand for triple-combination respiratory treatments.

· July 2026: GSK reaffirmed its 2026 turnover growth guidance of 3% to 5%, despite pricing and competitive pressures affecting certain respiratory products.

The companies profiled in the FMI report include:

· GlaxoSmithKline (GSK)

· AstraZeneca

· Novartis AG

· Boehringer Ingelheim

· Chiesi Farmaceutici

· Teva Pharmaceutical Industries

· Cipla

· Mylan

· Beximco Pharmaceuticals

· Elpen

· Vectura Group

· Hovione

· AptarGroup

· Iconovo (Stevanato Group)

· MannKind

· Pharmaxis

· Sava Healthcare

Where to Act and Where to Be Careful

For pharmaceutical manufacturers, multi-dose inhaler development remains an important strategic area. These devices offer convenient dosing and are widely used for daily respiratory maintenance therapies. Investment in device design, formulation development and combination treatments can help manufacturers strengthen their competitive positions.

Asthma and COPD also represent significant opportunities. With asthma accounting for 42.7% and COPD approximately 38.9% of indication demand in 2026, manufacturers can prioritize therapies addressing chronic respiratory conditions.

Emerging markets provide another growth opportunity. India and ASEAN are expected to outperform the global market growth rate, supported by improving access to respiratory treatments and increasing diagnosis rates. Cost-effective single-dose capsule inhalers can help manufacturers address affordability requirements in these markets.

However, companies should carefully evaluate generic competition, pricing pressure, regulatory requirements and manufacturing costs. The development of lower-carbon metered dose inhalers also presents a competitive challenge, potentially influencing prescribing preferences and device selection.

Access Full Report: https://www.futuremarketinsights.com/reports/dry-powder-inhaler-market

Analyst Perspective

Anurag Sharma, Principal Consultant at Future Market Insights, observes:

“Dry powder inhalers are shifting from blockbuster combinations to a mix of generics and once-daily triple therapies. Growth will come from widening access in emerging markets more than from price. Low carbon propellant inhalers will compete hard for new patients, so powder device makers need to prove ease of use and lower total cost.”

FMI's analysis indicates that respiratory disease prevalence, affordable inhaler availability, combination therapy innovation and emerging-market healthcare expansion will remain important influences on the industry's development through 2036.

Questions for Your Next Planning Meeting

How can manufacturers strengthen multi-dose inhaler portfolios to address growing demand for long-term asthma and COPD management?
Which geographical markets offer the strongest investment opportunities, particularly India, ASEAN and China?
How can pharmaceutical companies balance affordable generic inhalers, advanced triple therapies and lower-carbon respiratory delivery technologies?
Explore the Full Dry Powder Inhaler Market Research

Businesses evaluating market entry, product development or investment opportunities can access FMI's research for detailed market forecasts, competitive intelligence, segment analysis and regional assessments.

Related FMI Reports:

· Respiratory Inhaler Devices Market – https://www.futuremarketinsights.com/reports/respiratory-inhaler-devices-market

· Digital Health Market – https://www.futuremarketinsights.com/reports/global-digital-health-market

· Personalized Medicine Market – https://www.futuremarketinsights.com/reports/personalized-medicine-market

About Future Market Insights (FMI)

Future Market Insights (FMI) is the publisher of the Dry Powder Inhaler Market research report. Its research provides market forecasts, company share analysis, competitive intelligence, market dynamics, challenges and strategic growth initiatives to support business planning and investment decisions.

Media and Business Enquiries

Future Market Insights

Email: [email protected]
Phone: +44 20 3769 9709 | +1 347 918 3531
Website: https://www.futuremarketinsights.com/